EN DE
Watch CV Sciences Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CV Sciences Inc (CVSI) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of CV Sciences Inc stock $0.01, price $0.01, that is 3.2% below the price, quality 38 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CS CV Sciences Inc logo Thin data Nov 10, 2026

CV Sciences Inc

CVSI · US
Low Priority

The stock costs about what our calculation considers fair.

Fair value $0.0090 · Fairly valued
Moderate debt
Revenue last quarter 18% below a year ago.
Quality 38/100
Weak Growth (revenue 5y −10.8 %/yr in USD)
Loss-making · -15.7% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 6/100 · thin data
Thin data
Estimate
Watch CV Sciences Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.3500 $0.0090 Fair Value $0.0090 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.0090 – $0.3500 · fair‑value band $0.0088 – $0.0092 · the $0.0093 price screens above the $0.0090 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow CV Sciences in your weekly email

Every Wednesday you see whether CV Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CV Sciences, Inc. engages in the development, manufacture, marketing, and sale of herbal supplements, hemp-based cannabidiol (CBD), and plant-based food products in North America.

Show moreShow less

It offers its products under the PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers.

The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Stock analysis

CV Sciences Inc (CVSI) currently trades at $0.0093, while our estimate is $0.0090, so the stock looks roughly fairly valued today (gap 3.3%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.0088 (bear) to $0.0092 (bull), the price of $0.0093 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

CV Sciences Inc reported revenue of $13.8M in FY2025 versus $20.0M in FY2021, a compound −8.9%/yr. Reported net income was −$958K in FY2025.

Key figures

Market cap $2.1M Micro · P/S ratio 0.18 · EPS (TTM) $−0.0200 · Net margin −6.9% · Return on equity −119% · Return on assets (EBIT) −30.7% (5-year average) · Operating margin −10.1% · Revenue (TTM) $12.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 90% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −3%, CVSI screens cheaper than that median.

Fair Value

Bear $0.0088 Fair Value $0.0090 Bull $0.0092
Price $0.0093 · Downside -3.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 40
How much profit the company makes from its sales and capital
Quality Growth 67
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 10
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 49
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 47
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyCharlie E Cheever III10% owner5,740,816 shares at $0.0200$114,816Aug 7, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−12.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.8%
Start year 2020 (pandemic). Over 10 years: +1.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−92.5% (2020) → −3.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch CVSI, get fair value alerts →

Compare CV Sciences Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −3.2% · Above median
Profitability
Return on assets −13.8% · Bottom 25%
Net margin (12 months) −15.7% · Bottom 25%
Operating margin (12 months) −10.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −17.5% · Bottom 25%
Balance sheet
Debt / equity 0.99× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.43× · Cheaper than median
P/S (12 months) 0.17× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)29 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)51 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs CVSI
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs CVSI
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs CVSI
Haleon plc HLN $9.06 $8.62 −5% vs CVSI
Merck KGaA MRK €149.35 €109.18 −27% vs CVSI
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs CVSI
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs CVSI
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs CVSI
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs CVSI
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs CVSI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CV Sciences Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CV Sciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/CVSI

Frequently asked questions

Is CV Sciences Inc (CVSI) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.0090 versus a price of $0.0093, about 3% lower (fairly valued).
What is the fair value of CVSI?
Our estimate for CV Sciences Inc is $0.0090 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.0093.
What is the quality score of CVSI?
CV Sciences Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CV Sciences Inc (CVSI)?
Our calculated price target is the estimate of $0.0090 (as of Nov 10, 2026). Cautious scenario $0.0088, optimistic scenario $0.0092. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CV Sciences Inc stock forecast for 2026?
Our estimate puts fair value at $0.0090, about 3% lower versus a price of $0.0093 (fairly valued). Cautious scenario $0.0088, optimistic scenario $0.0092. The calculation is refreshed regularly with new filings.
What is the revenue of CV Sciences Inc (CVSI)?
CV Sciences Inc reported trailing-twelve-month revenue of about $12.7M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of CV Sciences Inc (CVSI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CV Sciences Inc it is $0.0090 per share (as of Nov 10, 2026), against a price of $0.0093.
Is CV Sciences Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CVSI trades above its calculated fair value: price $0.0093, fair value $0.0090, a gap of about −3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CVSI?
No. The price is what the market pays today ($0.0093); the fair value is what the company's own numbers justify ($0.0090). For CV Sciences Inc the two are $0.0003 per share apart. That gap is exactly why we show both numbers side by side.
How much is CV Sciences Inc worth?
The market values CV Sciences Inc at about $2.1M (market capitalisation, as of Nov 10, 2026). Per share that is $0.0093; our models calculate a fair value of $0.0090 per share.
What do the bullish and bearish scenarios say about CVSI?
Our models span a range for CV Sciences Inc: cautious scenario $0.0088, base $0.0090, optimistic $0.0092 per share (as of Nov 10, 2026, price $0.0093). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CV Sciences Inc (CVSI)?
Balance-sheet figures for CV Sciences Inc (as of Nov 10, 2026): return on equity −118.9%, debt of 0.99 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is CVSI from its 52-week high?
CV Sciences Inc trades at $0.0093, about 90% below its 52-week high of $0.0900 and 3% above the low of $0.0090 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0090 is for.
Which stocks are comparable to CV Sciences Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CV Sciences Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.0093, calculated fair value $0.0090 (−3%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. CV Sciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CV Sciences Inc (CVSI)?
The closing price on Nov 10, 2026 was $0.0093. Our estimate is $0.0090, about 3% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CV Sciences Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0088 to $0.0092), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of CV Sciences Inc

How large is the market capitalisation of CV Sciences Inc (CVSI)?
The market capitalisation of CV Sciences Inc is $2.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CV Sciences Inc (CVSI)?
The price-to-sales ratio of CV Sciences Inc is 0.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CV Sciences Inc (CVSI)?
Earnings per share at CV Sciences Inc are $−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CV Sciences Inc (CVSI)?
The net margin of CV Sciences Inc is −6.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CV Sciences Inc (CVSI)?
The return on equity (ROE) of CV Sciences Inc is −119% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CV Sciences Inc (CVSI)?
On an EBIT basis the return on assets of CV Sciences Inc is −30.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CV Sciences Inc (CVSI)?
The operating margin of CV Sciences Inc is −10.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CV Sciences Inc (CVSI)?
Revenue at CV Sciences Inc is growing −17.5% versus a year earlier (3y avg −5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CV Sciences Inc (CVSI) generate?
The free cash flow of CV Sciences Inc is −$516K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CV Sciences Inc (CVSI) carry?
The net debt of CV Sciences Inc is $984K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CV Sciences Inc in the live analysis

One click puts CV Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.